-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042

PUBT·06/30/2026 12:04:14
Listen to the news
Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042
  • Allarity Therapeutics received a key U.S. patent for its stenoparib DRP companion diagnostic, extending protection into April 2042.
  • Coverage includes methods to predict stenoparib benefit from tumor gene-expression profiles, supporting patient selection in clinical use.
  • Exclusivity targets U.S. commercialization of stenoparib when paired with the DRP test, reinforcing its ovarian cancer development strategy.
  • Separate patent protection for the stenoparib DRP runs to 2039 in Europe and Australia, with additional markets pending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED1001210389) on June 30, 2026, and is solely responsible for the information contained therein.